Partial Agonist and Biased Signaling Properties of the Synthetic Enantiomers J113863/UCB35625 at Chemokine Receptors CCR2 and CCR5

Biased Signaling at Chemokine Receptors

(2015) Jenny Corbisier et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Internalization of the chemokine receptor CCR4 can be evoked by orthosteric and allosteric receptor antagonists

(2014) Laura Ajram et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis

(2014) Yaniv Zohar et al.   JOURNAL OF CLINICAL INVESTIGATION

Distinct Conformations of the Chemokine Receptor CCR4 with Implications for Its Targeting in Allergy

(2014) J. M. Viney et al.   JOURNAL OF IMMUNOLOGY

Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers

(2014) David G. Soergel et al.   PAIN

Biased and G Protein-Independent Signaling of Chemokine Receptors

(2014) Anne Steen et al.   Frontiers in Immunology

CCL17/thymus and activation-regulated chemokine induces calcitonin gene–related peptide in human airway epithelial cells through CCR4

(2013) Kandace Bonner et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Biased and Constitutive Signaling in the CC-chemokine Receptor CCR5 by Manipulating the Interface between Transmembrane Helices 6 and 7

(2013) Anne Steen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Biased Agonism as a Mechanism for Differential Signaling by Chemokine Receptors

(2013) Sudarshan Rajagopal et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

First Clinical Experience with TRV027: Pharmacokinetics and Pharmacodynamics in Healthy Volunteers

(2013) David G. Soergel et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Signalling bias in new drug discovery: detection, quantification and therapeutic impact

(2013) Terry Kenakin et al.   NATURE REVIEWS DRUG DISCOVERY

Agonist-Induced Internalization of CC Chemokine Receptor 5 as a Mechanism to Inhibit HIV Replication

(2011) T. Ferain et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Functional Selectivity and Biased Receptor Signaling

(2010) T. Kenakin   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Selectively Engaging  -Arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac Performance

(2010) J. D. Violin et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Therapeutic potential of β-arrestin- and G protein-biased agonists

(2010) Erin J. Whalen et al.   TRENDS IN MOLECULAR MEDICINE

Chemokines and chemokine receptors: an overview

(2009) Raffaella Bonecchi   Frontiers in Bioscience-Landmark

 -Blockers alprenolol and carvedilol stimulate  -arrestin-mediated EGFR transactivation

(2008) I.-M. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Highly potent HIV inhibition: engineering a key anti-HIV structure from PSC-RANTES into MIP-1 /CCL4

(2008) H. Gaertner et al.   PROTEIN ENGINEERING DESIGN & SELECTION